Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
$0.00
▼
$0.05
$5K49.6617,928 shs73 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.193,541 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$1.65M1.3115,903 shs1,571 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00%0.00%0.00%-50.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%-33.33%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%+300.00%+300.00%0.00%-63.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
$0.00
▼
$0.05
$5K49.6617,928 shs73 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.193,541 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$1.65M1.3115,903 shs1,571 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00%0.00%0.00%-50.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%-33.33%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%+300.00%+300.00%0.00%-63.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-$30.37M$0.310.00N/AN/AN/AN/AN/A11/2/2026 (Estimated)
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
9.65%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
5.50%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
3053.32 million50.39 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
942.08 million39.94 millionNot Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionNo Data

Recent News About These Companies

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Above 50-Day Moving Average - Time to Sell?
September 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30995664
Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20210119006194/en/Syros-Announces-Pricing-of-%2475.6-Million-Public-Offering-of-Common-Stock
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rege-nephro-buys-tamibarotene-related-assets-from-syros-pharmaceuticals/ar-AA1CX7u7
Syros Pharmaceuticals trading resumes
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-trading-resumes-1034427505
Syros Pharmaceuticals Plans to Wind Down Operations
March 1, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/syros-pharmaceuticals-plans-to-wind-down-operations-948b139e
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-voluntarily-delists-from-nasdaq-deregisters-common-stock-1034427422
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
February 28, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250228459350/en/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration/
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/syros-pharmaceuticals-stock-hits-52-week-low-at-0-18-amid-steep-decline/ar-AA1y4cfB
Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?
January 18, 2025  |  bovnews.comB
What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?
January 16, 2025  |  bovnews.comB
SYRS’s Latest Surge: What’s Behind the Spike?
January 6, 2025  |  bovnews.comB
The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again
January 2, 2025  |  bovnews.comB
Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?
December 31, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears
December 27, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed
December 26, 2024  |  bovnews.comB
What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?
December 14, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?
December 7, 2024  |  bovnews.comB
Why Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?
December 5, 2024  |  bovnews.comB
Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock
December 5, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-syrs-insider-buying-and-selling-2024-12-05/
Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright
December 2, 2024  |  bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aridis Pharmaceuticals stock logo

Aridis Pharmaceuticals NASDAQ:ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 09/4/2026

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 09/4/2026 03:55 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas